{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:53:25Z","timestamp":1789458805125,"version":"build-2803163510"},"reference-count":50,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rising BCR-ABL1 transcripts indicate potential loss of imatinib response in CML. We determined whether the BCR-ABL1 doubling time could distinguish nonadherence from resistance as the cause of lost response. Distinct groups were examined: (1) acquired clinical resistance because of blast crisis and\/or BCR-ABL1 mutations; and (2) documented imatinib discontinuation\/interruption. Short doubling times occurred with blast crisis (median, 9.0 days; range, 6.1-17.6 days; n = 12 patients), relapse after imatinib discontinuation in complete molecular response (median, 9.0 days; range, 6.9-26.5 days; n = 17), and imatinib interruption during an entire measurement interval (median, 9.4 days; range, 4.2-17.6 days; n = 12; P = .72). Whereas these doubling times were consistently short and indicated rapid leukemic expansion, fold rises were highly variable: 71-, 9.5-, and 10.5-fold, respectively. The fold rise depended on the measurement interval, whereas the doubling time was independent of the interval. Longer doubling times occurred for patients with mutations who maintained chronic phase (CP: median, 48 days; range, 17.3-143 days; n = 29; P &lt; .0001). Predicted short and long doubling times were validated on an independent cohort monitored elsewhere. The doubling time revealed major differences in kinetics according to clinical context. Long doubling times observed with mutations in CP allow time for intervention. A short doubling time for a patient in CP should raise the suspicion of nonadherence.<\/jats:p>","DOI":"10.1182\/blood-2011-11-393041","type":"journal-article","created":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T05:21:23Z","timestamp":1332220883000},"page":"4264-4271","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management"],"prefix":"10.1182","volume":"119","author":[{"given":"Susan","family":"Branford","sequence":"first","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"},{"name":"Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi A.","family":"Prime","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Young","family":"Choi","sequence":"additional","affiliation":[{"name":"Molecular Genetics Research Institute, Catholic University of Korea, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-hee","family":"Bang","sequence":"additional","affiliation":[{"name":"Molecular Genetics Research Institute, Catholic University of Korea, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Eok","family":"Park","sequence":"additional","affiliation":[{"name":"Molecular Genetics Research Institute, Catholic University of Korea, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"Molecular Genetics Research Institute, Catholic University of Korea, Seoul, South Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"},{"name":"Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"Department of Haematology and Genetic Pathology, Flinders University and Medical Centre, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"},{"name":"Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"35","key":"2019111808282972400_B1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111808282972400_B2","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111808282972400_B3","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"issue":"20","key":"2019111808282972400_B4","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111808282972400_B5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2009.07646.x","article-title":"Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?","volume":"145","author":"Marin","year":"2009","journal-title":"Br J Haematol"},{"issue":"14","key":"2019111808282972400_B6","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111808282972400_B7","unstructured":"O'Brien S NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, Version 2.2012. Accessed July 11, 2011 http:\/\/wwwnccnorg\/professionals\/physician"},{"issue":"13","key":"2019111808282972400_B8","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111808282972400_B9","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473","article-title":"Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.","volume":"87","author":"Lin","year":"1996","journal-title":"Blood"},{"issue":"4","key":"2019111808282972400_B10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/(SICI)1096-9098(199812)69:4<206::AID-JSO3>3.0.CO;2-N","article-title":"Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma.","volume":"69","author":"Ollila","year":"1998","journal-title":"J Surg Oncol"},{"issue":"10","key":"2019111808282972400_B11","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/clinchem\/45.10.1695","article-title":"Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring.","volume":"45","author":"Bidart","year":"1999","journal-title":"Clin Chem"},{"issue":"3","key":"2019111808282972400_B12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijgo.2004.12.028","article-title":"CA 125 half-life breakpoint between a \u201cgood\u201d and \u201cpoor\u201d prognosis in patients with ovarian cancer.","volume":"88","author":"Mano","year":"2005","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"2019111808282972400_B13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2265.2009.03666.x","article-title":"Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.","volume":"72","author":"Meijer","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2019111808282972400_B14","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response.","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111808282972400_B15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20096","article-title":"Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.","volume":"76","author":"Higashi","year":"2004","journal-title":"Am J Hematol"},{"issue":"7046","key":"2019111808282972400_B16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia.","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"22","key":"2019111808282972400_B17","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2019111808282972400_B18","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111808282972400_B19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111808282972400_B20","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy.","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111808282972400_B21","first-page":"209","article-title":"Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDEL-II trial [abstract].","volume":"116","author":"Yeung","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"2019111808282972400_B22","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2019111808282972400_B23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111808282972400_B24","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111808282972400_B25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111808282972400_B26","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"issue":"19","key":"2019111808282972400_B27","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111808282972400_B28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111808282972400_B29","first-page":"2763","article-title":"Discontinuation of imatinib therapy in chronic myeloid leukemia patients with sustained complete molecular response4.5 (CMR4.5) [abstract].","volume":"118","author":"Goh","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111808282972400_B30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood-2009-04-212530","article-title":"Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.","volume":"115","author":"Ommen","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111808282972400_B31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2019111808282972400_B32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111808282972400_B33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP).","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"issue":"24","key":"2019111808282972400_B34","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"29","key":"2019111808282972400_B35","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111808282972400_B36","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"issue":"51","key":"2019111808282972400_B37","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111808282972400_B38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111808282972400_B39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111808282972400_B40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/leu.2011.187","article-title":"Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.","volume":"26","author":"Gruber","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"2019111808282972400_B41","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111808282972400_B42","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111808282972400_B43","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111808282972400_B44","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2019111808282972400_B45","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"issue":"25","key":"2019111808282972400_B46","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111808282972400_B47","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1742-1241.2008.01941.x","article-title":"Targets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes.","volume":"62","author":"Woo","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"11","key":"2019111808282972400_B48","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe.","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2019111808282972400_B49","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111808282972400_B50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication.","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/18\/4264\/1352672\/zh801812004264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/18\/4264\/1352672\/zh801812004264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T07:56:41Z","timestamp":1641369401000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/18\/4264\/30086\/BCRABL1-doubling-times-more-reliably-assess-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,3]]},"references-count":50,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012,5,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-11-393041","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,3]]}}}